"Differences in favor of vonoprazan were greater in patients with LA grade C/D esophagitis than in those with LA grade A/B esophagitis ... Gastroesophageal reflux disease (GERD) remains one ...

Longitudinal mucosal breaks tended to be located most frequently in the 2 o'clock position in patients with low grade reflux esophagitis, including LA grades A and B. The longitudinal mucosal ...

Esophagitis is inflammation of the esophagus, the tube that carries food from your mouth to your stomach, and can be caused by various factors including acid reflux, infections, and immune reactions.

Results from the dual Phase III TRIUMpH trials demonstrated the statistical superiority of tegoprazan over lansoprazole in patients with erosive esophagitis and non-erosive reflux disease ...

In addition, vonoprazan showed superior rates of healing in patients with moderate-to-severe disease (LA Grade C/D ... many GERD patients with erosive esophagitis, the response to current ...

As compared with patients with erosive esophagitis ... A and B) for a mean duration of 5.5 years. Only 10.5% of the patients progressed to higher grading (mostly Los Angeles grade C) and none ...

Tegoprazan met all primary and secondary endpoints in non-erosive reflux disease (NERD ... including 463 patients with LA Grade C/D esophagitis) evaluating the safety and efficacy of tegoprazan ...

There was significant improvement seen in reflux esophagitis in ARMS versus ARMA, with notable changes seen in Los Angeles grade and flap valve grade scores. Comparable improvement in Barrett ...

The Food and Drug Administration (FDA) has approved Voquezna (vonoprazan) for healing and maintenance of healing, of all grades of erosive esophagitis ... severe disease (LA Grade C or D disease ...

Caselberg’s diagnosis included moderate inflammation of the food pipe caused by acid reflux (Grade B reflux esophagitis), a large hernia where part of the stomach pushes into the chest (large ...